Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium
about
Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase.A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms.Acute myeloid leukemia following a myeloproliferative neoplasm: clinical characteristics, genetic features and effects of therapy.Secondary acute myeloid leukemias arising from Philadelphia chromosome negative myeloproliferative neoplasms: pathogenesis, risk factors, and therapeutic strategies.Blast-phase myeloproliferative neoplasms: risk factors and treatment approaches.Allo-SCT for Philadelphia-negative myeloproliferative neoplasms in blast phase: a study from the Societe Française de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC).Decitabine treatment of multiple extramedullary acute myeloid leukemia involvements after essential thrombocytemia transformation.The combination treatment regimen of ruxolitinib with low-dose mercaptopurine or cytarabine in frail patients with blast-phase myelofibrosis.Impact of gene mutations on treatment response and prognosis of acute myeloid leukemia secondary to myeloproliferative neoplasms.Mediator Kinase Phosphorylation of STAT1 S727 Promotes Growth of Neoplasms With JAK-STAT Activation.Combination therapy with ruxolitinib plus intensive treatment strategy is feasible in patients with blast-phase myeloproliferative neoplasms.
P2860
Q35988523-2AAC0FAB-6AD7-495C-A355-DEF2A7509A76Q37676277-C6400D72-8FAF-41BD-B0B1-B6BC44685BA4Q38097735-C0AB9961-2A34-494A-9690-5FD9EDF6B358Q38429716-A5AAFDC4-922C-4F67-9441-0C792AD6F167Q38844669-2DFF1E8D-BE5D-4CAB-B323-A077F91776DDQ44380116-93CD6790-96B5-4279-93B4-75413E3C8BE4Q48165068-6BE833D6-CD8A-469C-BE98-29946EA1B472Q48203984-662CEB55-F039-49AF-97B2-C885F5D92D10Q48284602-947DA56D-E4C0-4E5F-8139-B6A0AB2BBD53Q48569638-2B86CA55-AFFF-4FB1-B51B-2175E00AF413Q50965749-7C819B1E-928F-4A2B-8867-F6DC7A7AE540
P2860
Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Proposed criteria for response ...... te myeloid leukemia consortium
@en
Proposed criteria for response ...... ative neoplasms in blast phase
@nl
type
label
Proposed criteria for response ...... te myeloid leukemia consortium
@en
Proposed criteria for response ...... ative neoplasms in blast phase
@nl
prefLabel
Proposed criteria for response ...... te myeloid leukemia consortium
@en
Proposed criteria for response ...... ative neoplasms in blast phase
@nl
P2093
P2860
P50
P1433
P1476
Proposed criteria for response ...... te myeloid leukemia consortium
@en
P2093
Bruce Petersen
Elizabeth Hexner
Eric Feldman
Gail Roboz
John Mascarenhas
Mark L Heaney
Nikolai Podoltsev
Post-myeloproliferative neoplasm acute myeloid leukemia consortium
Raajit Rampal
P2860
P304
P356
10.1016/J.LEUKRES.2012.08.013
P577
2012-08-28T00:00:00Z